Colon-specific adhesion microsphere for treating ulcerative colitis as well as preparation method and application of colon-specific adhesion microsphere
By using adhesion coating technology of microsphere shells and white and polysaccharides crosslinked by sodium alginate and calcium ion in the treatment of ulcerative colitis, the stability and target of berberine hydrochloride in the treatment of ulcerative colitis was solved. The tropism problem has achieved efficient targeted colonic administration, significantly improving the therapeutic effect and reducing adverse reactions.
Patent Information
- Application Number
- CN202410945308.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
The existing berberine hydrochloride (BH) preparations are difficult to achieve effective colon targeted treatment due to poor stability, low bioavailability and excessive adverse reactions in the treatment of ulcerative colitis.
The microsphere shell formed by crosslinking sodium alginate and calcium ions is used to combine the adhesion of white and polysaccharides. Calcium alginate microspheres containing berberine hydrochloride phospholipid complex were prepared by electrostatic spraying method, and the adhesion was wrapped inside it. The inner layer and the pH-sensitive outer layer are coated to form a colonic targeted drug delivery system with cascade delivery function.
It significantly improves the residence time and targeting of the drug in the colon, enhances adhesion and accumulation in inflamed tissues, improves the treatment effect of ulcerative colitis, and reduces the occurrence of adverse reactions.
Smart Images

Figure CN118903057A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a colon-localized adhesion microsphere for treating ulcerative colitis, and a preparation method and application thereof. Background Art
[0002] Ulcerative colitis (UC) is a chronic nonspecific inflammatory bowel disease with unclear causes. Clinically, it is characterized by abdominal pain, diarrhea, weight loss, and bloody stools with mucus and pus. It is currently believed that the etiology of ulcerative colitis is mainly the result of the interaction of multiple factors such as immunity, genetics, infection, diet, and mental health. The core is closely related to intestinal barrier dysfunction, imbalance of intestinal symbiotic microorganisms, and intestinal immune response disorders, which ultimately lead to severe inflammatory reactions. In recent years, with the modernization of lifestyles and environmental exposure, the incidence and prevalence of UC have increased rapidly, and are becoming younger.
[0003] Berberine hydrochloride (BH) has the effects of repairing intestinal mucosa, antibacterial and anti-diarrhea, anti-oxidative stress properties, and regulating intestinal mucosal permeability. Currently, commercially available BH preparations are mainly tablets, which are suitable for treating gastrointestinal inflammation and infection. BH is an alkaloid with poor stability and low bioavailability. It is also a substrate for efflux transporters (P-gp), which makes it difficult to stay in the intestine and has poor therapeutic effects. Excessive BH can also cause adverse reactions such as anaphylactic shock and drug rash. In order to increase the retention time of berberine hydrochloride in the body, berberine hydrochloride is combined with aluminum phosphate gel enema clinically, so that berberine hydrochloride is retained in the intestine for a long time, and the therapeutic effect is improved. Prolonging the retention time of berberine hydrochloride in the intestine is a promising treatment for colitis. However, enema administration is inconvenient to use, especially for patients with chronic diseases who require long-term treatment. Its compliance and acceptability are usually low. Therefore, it is urgent to develop an oral drug delivery system that can be localized to the site of colon inflammation.
[0004] Microspheres (MPs) based on polysaccharides can protect the nanoparticles and deliver them to the colon intact, and have the ability of colon intelligent release, including pH sensitivity, time response, colon microbial response and drug sustained release. Alginate is a polysaccharide derived from nature. As a safe excipient recognized by the US Food and Drug Administration (FDA), it is widely used in the field of drug research and development. Bletillastriata polysaccharides (BSP) are a kind of viscous polysaccharide extracted from Bletilla striata. Its main component is glucomannan, which contains mannose and glucose in a ratio of about 3:1 or 7:2. These substances have pharmacological activities such as hemostasis, coagulation, anti-inflammatory, antioxidant and anti-tumor. Studies have shown that BSP and BH can upregulate the expression of occludin protein in the treatment of colitis, achieving the effect of treating colitis. Studies have shown that BSP has certain bioadhesion properties, and its adhesion can be enhanced when used in combination with bioadhesive polymers such as sodium alginate. In addition, studies have shown that BSP can be added to microspheres to enhance the adhesion of the microspheres.
[0005] Oral colon-targeted drug delivery system (OCDDS) is a new type of targeted drug delivery system that uses drug delivery technology to ensure that the drug is not released in the upper digestive tract after oral administration, but is transported to the ileocecal region and then released in the colon to exert local or systemic therapeutic effects. OCDDS can significantly enhance local efficacy, reduce adverse reactions, and make up for the shortcomings of many traditional oral preparations. It has broad application prospects in the treatment of many gastrointestinal diseases such as ulcerative colitis, Kernrow's disease, colon cancer, etc. Summary of the invention
[0006] The purpose of the present invention is to provide a colon-localized adhesive microsphere for treating ulcerative colitis and its preparation method and application. In order to circumvent the limitation of oral administration of BH and ensure that BH is smoothly delivered to the colon, sodium alginate (AG) is cross-linked with calcium ions to form a microsphere (MPs) shell. In order to prevent the single-layer structure from being easily damaged and leaked, a bioadhesive drug delivery system with cascade delivery function and colon targeting capability is constructed by the technical means of multi-layer sodium alginate hydrogel to encapsulate BH. By adding a specific concentration of BSP to the microsphere, the therapeutic effects of BSP in wound healing, hemostasis, antibacterial and anti-inflammatory aspects and its own adhesion can be utilized to enhance the adhesion ability of the microsphere and achieve a synergistic function. Finally, MPs, as a large-volume "warehouse" of BH, responds to release BH after arriving at the colon, and BSP and SA exert biological adhesion ability, so that the "warehouse" adheres to the colon inflammation environment and continuously releases drugs, thereby enhancing the adhesion and accumulation of BH in the inflamed colon tissue, and can exert a good therapeutic effect.
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides a colon-localized adhesive microsphere for treating ulcerative colitis, comprising calcium alginate microspheres containing berberine hydrochloride phospholipid complexes, an adhesive inner coating and a pH-sensitive outer coating, wherein the outside of the calcium alginate microspheres containing berberine hydrochloride phospholipid complexes is sequentially coated with a Bletilla striata polysaccharide coating with adhesive ability and a pH-sensitive outer coating.
[0009] Furthermore, the raw materials of the calcium alginate microspheres containing berberine hydrochloride phospholipid complex include sodium alginate solution, berberine hydrochloride phospholipid complex, and calcium chloride solution, wherein:
[0010] The mass fraction of the sodium alginate solution includes 0.5 to 2%; the mass fraction of the calcium chloride solution includes 2 to 6%;
[0011] The mass ratio of sodium alginate to berberine hydrochloride phospholipid complex is 0.5:1-2:1.
[0012] Furthermore, the raw materials of the berberine hydrochloride phospholipid complex include berberine hydrochloride and hydrogenated lecithin; wherein the mass ratio of berberine hydrochloride to hydrogenated lecithin is 0.5:1 to 1:4.
[0013] Furthermore, the raw materials of the adhesive inner layer coating include 6% to 10% by mass of Bletilla striata polysaccharide solution, and the remainder is pure water.
[0014] Further, the coating weight gain of the pH-sensitive outer coating is 10%-15% of the weight of the colon-localized adhesive microspheres for treating ulcerative colitis;
[0015] The preparation liquid of the pH sensitive outer layer coating comprises the following raw materials: acrylic resin, plasticizer, anti-sticking agent and organic solvent;
[0016] The weight ratio of each component includes acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
[0017] Further, the acrylic resin includes Eudragit enteric-coated series products;
[0018] The plasticizer includes triethyl citrate, sorbitol or polyethylene glycol;
[0019] The anti-adhesive agent includes talc or dextrin;
[0020] The organic solvent includes ethanol at a volume concentration of 70-95%.
[0021] The present invention also provides a method for preparing the colon-localized adhesion microspheres for treating ulcerative colitis as described above, comprising the following steps:
[0022] Based on berberine hydrochloride and hydrogenated lecithin, berberine hydrochloride phospholipid complex is prepared;
[0023] Based on sodium alginate solution, calcium chloride solution and berberine hydrochloride phospholipid complex, calcium alginate microspheres containing berberine hydrochloride phospholipid complex are prepared;
[0024] The calcium alginate microspheres containing the berberine hydrochloride phospholipid complex are coated with an adhesive inner layer to obtain a coating of Bletilla striata polysaccharide having an adhesive ability;
[0025] The Bletilla striata polysaccharide coating with adhesion ability is coated with a pH-sensitive outer layer to form colon-localized adhesion microspheres for treating ulcerative colitis.
[0026] Furthermore, the calcium alginate microspheres containing the berberine hydrochloride phospholipid complex are coated with an adhesive inner layer to obtain a Bletilla striata polysaccharide coating having an adhesive ability, comprising:
[0027] Pre-coating the calcium alginate microspheres containing berberine hydrochloride phospholipid complex with chitosan;
[0028] The pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex are immersed in a Bletilla striata polysaccharide solution to obtain a Bletilla striata polysaccharide coating having adhesion ability.
[0029] Furthermore, the calcium alginate microspheres containing berberine hydrochloride phospholipid complex are pre-coated with chitosan, comprising:
[0030] Prepare a chitosan aqueous solution; wherein the mass fraction of the chitosan solution is 0.5-1.5%;
[0031] The calcium alginate microspheres containing berberine hydrochloride phospholipid complex are placed in a chitosan solution and stirred for a first predetermined time, filtered, and dried to obtain pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex.
[0032] Furthermore, the pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex are immersed in a Bletilla striata polysaccharide solution to obtain a Bletilla striata polysaccharide coating having adhesion ability, comprising:
[0033] preparing a Bletilla striata polysaccharide solution, wherein the mass fraction of the Bletilla striata polysaccharide solution is 8%;
[0034] A predetermined mass of pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex is taken and immersed in a Bletilla striata polysaccharide solution. After stirring for a second predetermined time, the solution is filtered and dried to obtain a Bletilla striata polysaccharide coating having adhesion ability.
[0035] Furthermore, the Bletilla striata polysaccharide coating with adhesion ability is coated with a pH-sensitive outer layer to form colon-localized adhesion microspheres for treating ulcerative colitis, comprising:
[0036] The polysaccharide coating of Bletilla striata with adhesion ability is placed in a preparation solution containing a pH-sensitive outer coating and preheated to make the microspheres in a suspended state;
[0037] The microspheres are coated under preset coating conditions until the pH-sensitive layer coating covering the Bletilla striata polysaccharide coating with adhesion ability reaches a preset coating weight gain, thereby obtaining colon-localized adhesion microspheres for the treatment of ulcerative colitis.
[0038] Furthermore, the formulation containing the pH sensitive outer coating is prepared by the following method:
[0039] Adding acrylic resin into an organic solvent and stirring thoroughly to obtain a mixed solution A;
[0040] Add plasticizer and anti-adhesive agent to the other half of the organic solvent and mix well to form a mixed solution B;
[0041] Adding the mixed solution B to the mixed solution A and mixing them to obtain a preparation solution for a pH-sensitive outer coating;
[0042] The weight ratio of each component includes: acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
[0043] Furthermore, the preset coating conditions are: temperature of 40-55°C, peristaltic flow rate of coating liquid of 3-8rpm / min, and rotation speed of coating barrel of 50-150rpm / min.
[0044] Furthermore, the preset coating weight gain is 8-12% of the coating weight gain of the pH-sensitive layer coating that wraps the Bletilla striata polysaccharide coating with adhesion ability.
[0045] The present invention provides the use of the colon-localized adhesion microspheres for treating ulcerative colitis as described above in the preparation of a drug for treating ulcerative colitis.
[0046] Technical effects and advantages of the present invention:
[0047] The present invention first prepares a phospholipid complex of a drug and hydrogenated lecithin, then suspends the drug phospholipid complex in a sodium alginate solution and prepares microspheres by an electrostatic spray method, utilizes the water absorption of the microspheres to absorb a bletilla striata polysaccharide solution to coat the bletilla striata polysaccharide adhesion layer, and finally uses a pH-sensitive enteric material EudragitES100 for a final coating to prepare drug colon-localized adhesion microspheres. The microspheres have a small particle size, a high drug loading and an encapsulation rate, and can prevent the drug from dissolving in the stomach and small intestine, and can be effectively transported to the colon and continuously and slowly release the drug. In addition, the adhesion of bletilla striata polysaccharide can make the microspheres adhere to and stay in the intestine for a long time, thereby enhancing the adhesion and accumulation of the drug in the inflamed colon tissue; the in vivo efficacy shows that the drug colon-localized adhesion microspheres can significantly improve the symptoms of weight loss and shortened colon length in mice, and reduce rectal bleeding, spleen weight and histological scores, indicating that the preparation can significantly improve the therapeutic effect of the drug against ulcerative colitis.
[0048] Berberine hydrochloride preparation BH and hydrogenated soybean phospholipids (HPC) were prepared into berberine hydrochloride phospholipid complex (BH-HPC), and then the phospholipid complex was encapsulated into sodium alginate microspheres by electrostatic spraying to obtain calcium alginate microspheres containing berberine hydrochloride phospholipid complex (AG-MPs@BH-HPC), which were then coated with BSP and Eudragit-S100 (ES) in turn to prepare microspheres with colon targeted adhesion ability (ES-BSP-MPs@BH-HPC), and the therapeutic effect on colitis mice was investigated by oral administration.
[0049] The colon-localized adhesion microspheres for treating ulcerative colitis of the present invention can increase the residence time of the drug in the colon, enhance the targeting and bioavailability of the drug, and thus improve the therapeutic effect. At the same time, the preparation method of the present invention is simple and controllable, and is conducive to industrial production.
[0050] Other features and advantages of the present invention will be described in the following description, and partly become obvious from the description, or be understood by implementing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 This is a schematic diagram of an electrostatic spray device in a specific embodiment of the present invention;
[0052] Figure 2a This is a transmission electron microscopy image of berberine hydrochloride phospholipid complex in a specific embodiment of the present invention;
[0053] Figure 2b This is a scanning electron microscope of berberine hydrochloride phospholipid complex in a specific embodiment of the present invention;
[0054] Figure 2c The particle size analysis of berberine hydrochloride phospholipid complex by Malvern particle size analyzer in a specific embodiment of the present invention;
[0055] Figure 2d This is a differential scanning calorimetry (DSC) analysis of berberine hydrochloride phospholipid complex in a specific embodiment of the present invention;
[0056] Figure 2e This is the Fourier infrared FTIR analysis of berberine hydrochloride phospholipid complex in the specific embodiment of the present invention.
[0057] Figure 2f This is the X-ray diffraction XRD analysis of berberine hydrochloride phospholipid complex in a specific embodiment of the present invention;
[0058] Figure 3a The morphology of microspheres prepared at different AG solution concentrations (w / w%) in the specific embodiment of the present invention, wherein the left picture is an AG solution concentration of 0.5%, the middle picture is an AG solution concentration of 1%, and the right picture is an AG solution concentration of 1.5%, and the scale bar is 200 μm;
[0059] Figure 3b The morphology of microspheres prepared with different needle diameters in the specific embodiments of the present invention (the left picture shows a needle diameter of 18G, the middle picture shows a needle diameter of 26G, and the right picture shows a needle diameter of 28G, with a scale of 200 μm;
[0060] Figure 3cThe morphology of microspheres prepared at different propulsion speeds in the specific embodiments of the present invention, wherein the upper left picture shows a propulsion speed of 0.25 mL / min, the upper right picture shows a propulsion speed of 0.5 mL / min, the lower left picture shows a propulsion speed of 1.0 mL / min, and the lower right picture shows a propulsion speed of 2.0 mL / min,, scale 200 μm;
[0061] Figure 3d The morphology of microspheres prepared at different voltages in the specific embodiment of the present invention is shown in the left figure. The voltage is 10×10 3 V, the middle graph is the voltage 15×10 3 V, the right picture shows the voltage 20×10 3 V, scale bar 200 μm;
[0062] Figure 4 The effect of different dosages on the microsphere morphology in the specific embodiment of the present invention, wherein A represents a dosage of 1:0.5; B represents a dosage of 1:1; C represents a dosage of 1:1.5; D represents a dosage of 1:2;
[0063] Figure 5a The shear rate-dependent viscosity of BSP-coated microspheres with different mass fractions in the specific embodiment of the present invention;
[0064] Figure 5b The shear rate dependence of BSP coated microspheres in different pH environments in the specific embodiments of the present invention;
[0065] Figure 6 The in vitro release of microspheres with different weight gain of Eudragit S100 in the specific examples of the present invention (x±SD, n=3);
[0066] Figure 7 IVIS images of the gastrointestinal biodistribution of ES-BSP-MPs@BH-HPC-FITC, ES-MPs@BH-HPC-FITC and BSP-MPs@BH-HPC-FITC in mice at 4, 6, 8, 12 and 24 hours after administration in a specific embodiment of the present invention;
[0067] Figure 8a The weight change rate of each group of mice in the pharmacodynamic study on colitis mice in the specific embodiment of the present invention is Figure 1 ;
[0068] Figure 8b Figure 2 is the weight change rate of each group of mice in the pharmacodynamic study on colitis mice in the specific embodiment of the present invention;
[0069] Figure 8c The DAI scores of each group of mice in the pharmacodynamic study on colitis mice in the specific embodiment of the present invention are Figure 1 ;
[0070] Figure 8d Figure 2 is the DAI score of each group of mice in the pharmacodynamic study on colitis mice in a specific embodiment of the present invention;
[0071] Fig. 9 This is the observation of mouse inflammatory tissue in a specific embodiment of the present invention, wherein A represents a physical picture of the change in colon length of each group of mice; B represents a data picture of the change in colon length of each group of mice; C represents a physical picture of the change in spleen size of each group of mice; D represents a data picture of the change in spleen index of each group of mice;
[0072] Fig.10 This is the histological H&E staining evaluation of colon tissue in a specific embodiment of the present invention;
[0073] Fig.11 This is the pathological score of the colon tissue of each group of mice in the specific example of the present invention. DETAILED DESCRIPTION
[0074] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0075] To address the deficiencies of the prior art, the present invention discloses a colon-localized adhesive microsphere for treating ulcerative colitis, wherein the microsphere comprises calcium alginate microspheres containing berberine hydrochloride phospholipid complexes, and the outside of the calcium alginate microspheres is sequentially coated with an adhesive inner coating and a pH-sensitive outer coating.
[0076] In a specific embodiment of the present invention, the raw materials of the calcium alginate microspheres (AG-MPs@BH-HPC) containing berberine hydrochloride phospholipid complex include sodium alginate solution, berberine hydrochloride phospholipid complex, and calcium chloride solution, wherein the mass fraction of the sodium alginate solution includes 0.5-2%; the mass fraction of the calcium chloride solution includes 2-6%; the mass ratio of sodium alginate to berberine hydrochloride phospholipid complex is 0.5:1-2:1.
[0077] Berberine hydrochloride phospholipid complex is suspended in sodium alginate solution, and calcium chloride is configured into a solution with a mass fraction of 2 to 6%. The sodium alginate solution suspended with berberine hydrochloride phospholipid complex is sprayed into the calcium chloride solution using electrostatic spray to obtain calcium alginate microspheres containing berberine hydrochloride phospholipid complex (AG-MPs@BH-HPC).
[0078] In a specific embodiment of the present invention, the voltage of the electrostatic spray is 5-20 kV, the flow rate is 0.5-2 mL / min, and the needle diameter is 23-30 G.
[0079] In a specific embodiment of the present invention, the raw materials of the berberine hydrochloride phospholipid complex (BH-HPC) include the following raw materials: berberine hydrochloride, hydrogenated lecithin, methanol, and chloroform; wherein the mass ratio of berberine hydrochloride to hydrogenated lecithin is 0.5:1 to 1:4, berberine hydrochloride is dissolved in 20 times the volume of methanol, and hydrogenated lecithin is dissolved in 20 times the volume of chloroform.
[0080] In a specific embodiment of the present invention, the raw material of the adhesive inner coating includes 6% to 10% by mass of Bletilla striata polysaccharide (BSP) solution, and the remainder is pure water.
[0081] In a specific embodiment of the present invention, the preparation liquid of the pH sensitive outer coating comprises the following raw materials: acrylic resin, plasticizer, anti-sticking agent and organic solvent;
[0082] The weight ratio of each component includes: acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
[0083] The acrylic resin includes Eudragit enteric series products;
[0084] The plasticizer includes triethyl citrate, sorbitol, and polyethylene glycol;
[0085] The anti-adhesive agent includes talc and dextrin;
[0086] The organic solvent includes ethanol at a volume concentration of 70-95%.
[0087] The present invention also provides a method for preparing colon-localized adhesion microspheres for treating ulcerative colitis, comprising the following steps:
[0088] Step 1: preparing berberine hydrochloride phospholipid complex (BH-HPC) based on berberine hydrochloride and hydrogenated lecithin;
[0089] Step 2: Based on sodium alginate solution, calcium chloride solution and berberine hydrochloride phospholipid complex (BH-HPC), calcium alginate microspheres containing berberine hydrochloride phospholipid complex (AG-MPs@BH-HPC) were prepared;
[0090] Step 3: coating the calcium alginate microspheres containing berberine hydrochloride phospholipid complex with an adhesive inner layer to obtain microspheres coated with Bletilla striata polysaccharide having adhesive ability (BSP-MPs@BH-HPC);
[0091] Step 4: The microspheres coated with the Bletilla striata polysaccharide having adhesion ability are coated with a pH-sensitive outer layer to form colon-localized adhesion microspheres (ES-BSP-MPs@BH-HPC) for treating ulcerative colitis.
[0092] In a specific embodiment of the present invention, for step 1, berberine hydrochloride phospholipid complex is prepared based on berberine hydrochloride and hydrogenated lecithin, and the specific steps include:
[0093] To prepare a phospholipid complex of berberine hydrochloride (BH) and hydrogenated soybean phospholipids (HPC),
[0094] Take an appropriate amount of BH and dissolve it in methanol to obtain a BH methanol solution;
[0095] Take an appropriate amount of HPC, add it to chloroform, and use ultrasonic treatment to completely dissolve it to obtain an HPC chloroform solution;
[0096] The prepared BH methanol solution was slowly added dropwise to the HPC chloroform solution, and after sealing, it was stirred in a constant temperature water bath at 45-65°C for 1-6 hours. After that, the seal was opened and evaporated to dryness at 50°C to remove the solvent. To ensure that the sample was completely dried, it was vacuum dried overnight at 45°C to obtain berberine hydrochloride phospholipid phospholipid complex (BH-HPC); after drying, the obtained sample was ground into fine powder and sealed for subsequent use.
[0097] In a specific embodiment of the present invention, for step 2, the specific steps are as follows: solution preparation:
[0098] Step 201, electrospraying liquid: prepare a certain concentration of sodium alginate (AG) solution in a beaker, stir and dissolve, and electrospraying can be performed when there is no obvious precipitation. The mass fraction of the sodium alginate solution is 0.5-2%;
[0099] Step 202, receiving solution: weigh a certain mass of CaCl 2 Add CaCl prepared in pure water 2 The solution was placed in a petri dish for later use;
[0100] Step 203, the mass ratio of BH-HPC to sodium alginate is in the range of 0.5:1 to 2:1, and the mixture is suspended in the sodium alginate solution. The voltage of the high-voltage electrostatic generator is set to 15×10 3V, flow rate 0.5mL / min, needle diameter 26G, spray into calcium chloride solution to obtain calcium alginate microspheres (AG-MPs@BH-HPC) containing berberine hydrochloride phospholipid complexes, and use a sieve to filter out microspheres with a particle size of 200-800 microns.
[0101] like Figure 1 As shown, sodium alginate (AG) solution is loaded into a syringe. A stainless steel flat-blade needle is used instead of a traditional sharp needle. The flat-blade needle helps to form a more stable droplet jet, which is beneficial for the production of uniform microspheres (MPs). Setting up the receiving device: A 2 cm magnetic particle is added to the culture dish of the receiving liquid and stirring is turned on to ensure uniform distribution of microspheres in the receiving liquid and prevent particle aggregation. A metal ring is set between the syringe pump and the receiver, which may be used to further stabilize the electric field or guide the electrospray process. The distance from the needle to the metal ring is 2 cm, the distance from the needle to the surface of the receiving liquid is 9 cm, and the distance from the needle to the bottom of the beaker is 13 cm. These distance parameters are crucial to controlling the formation and flight trajectory of droplets during the electrospray process, and directly affect the size and morphology of the final product.
[0102] In a specific embodiment of the present invention, for step 3, the specific steps are as follows:
[0103] Step 301: preparing a chitosan aqueous solution; wherein the mass fraction of the chitosan solution is 0.5-1.5%;
[0104] Step 302: The calcium alginate microspheres (AG-MPs@BH-HPC) containing berberine hydrochloride phospholipid complex are placed in a chitosan solution and stirred for a first predetermined time, and then pre-coated, the microspheres are filtered out, and dried to obtain the pre-coated AG-MPs@BH-HPC for later use.
[0105] Step 303: preparing a Bletilla striata polysaccharide solution (BSP), wherein the mass fraction of the Bletilla striata polysaccharide solution is 6-12%;
[0106] Step 304: Take a predetermined mass of pre-coated AG-MPs@BH-HPC and immerse it in the Bletilla striata polysaccharide solution. After stirring for a second predetermined time, filter and dry to obtain a Bletilla striata polysaccharide coating (BSP-MPs@BH-HPC) having adhesion ability.
[0107] In a specific embodiment of the present invention, for step 4, the specific steps are as follows:
[0108] Step 401: Prepare a formulation containing a pH-sensitive outer coating:
[0109] Step 4011: adding acrylic resin to the organic solvent and stirring thoroughly to obtain a mixed solution A;
[0110] Step 4012: Add plasticizer and anti-adhesive agent to the other half of the organic solvent, and mix thoroughly to obtain a mixed solution B;
[0111] Step 4013: Add the mixed solution B to the mixed solution A and mix them to obtain a preparation solution for the pH sensitive outer coating; wherein the weight ratio of the components includes: acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
[0112] Step 402: taking the BSP-MPs@BH-HPC obtained in step 3 and placing it in a configuration liquid containing a pH-sensitive outer coating for preheating, and adjusting the induced draft fan frequency and the blower frequency in sequence after preheating to make the BSP-MPs@BH-HPC microspheres in a suspended state; wherein the preheating time is 5 minutes, the induced draft fan frequency is 35 Hz, and the blower frequency is 20 Hz;
[0113] Step 403: Coat the BSP-MPs@BH-HPC microspheres under the preset coating conditions until the pH-sensitive layer coating of the BSP-MPs@BH-HPC microspheres reaches the preset coating weight gain, take out the microspheres coated with the pH-sensitive layer and sieve them to obtain colon-localized adhesion microspheres (ES-BSP-MPs@BH-HPC) for the treatment of ulcerative colitis. Among them, the preset coating conditions are: temperature of 40°C, peristaltic flow rate of the coating liquid of 3rpm / min, and speed of the coating barrel of 100rpm / min. The preset coating weight gain is 10% of the pH-sensitive layer coating weight gain of the Bletilla striata polysaccharide coating with adhesion ability.
[0114] In the third aspect of the present invention, the present invention also provides the use of the colon-localized adhesion microspheres for treating ulcerative colitis as described above in drugs for treating ulcerative colitis.
[0115] The technical solution of the present invention will be further described below in conjunction with specific embodiments.
[0116] Example 1
[0117] Preparation method of berberine hydrochloride phospholipid complex
[0118] To prepare a phospholipid complex of berberine hydrochloride (BH) and hydrogenated soybean lecithin (HPC), first accurately weigh 100 mg of BH and dissolve it in 20 mL of methanol. Next, weigh 200 mg of HPC, add 20 times the volume of chloroform, and use ultrasonic treatment to completely dissolve it. Subsequently, the prepared BH methanol solution is slowly added dropwise to the HPC chloroform solution, sealed, and stirred in a constant temperature water bath at 45 ° C for 4 hours. After that, the seal is opened and evaporated at 50 ° C to remove the solvent. To ensure that the sample is thoroughly dried, vacuum dried overnight at 45 ° C to obtain berberine hydrochloride phospholipid phospholipid complex (BH-HPC). After drying, the obtained sample is ground into fine powder and sealed for subsequent use.
[0119] The drug loading efficiency (LD%) and encapsulation efficiency (EE%) of BH-HPC were measured, and the encapsulation efficiency and drug loading were 96.79±0.29% and 32.26±0.29%, respectively.
[0120] The characterization results of berberine hydrochloride phospholipid complex are as follows:
[0121] BH-HPC was characterized in vitro by X-ray diffraction (XRD), scanning electron microscope (SEM), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), particle size analysis (DA) and Fourier Transform Infrared Spectroscopy (FT-IR), and was compared with BH, HPC and a physical mixture of BH:HPC=1:1.
[0122] Figure 2a , 2bFigures 2c and 2c show the characterization of berberine hydrochloride phospholipid complex (BH-HPC) by transmission electron microscopy (scale 500 nm), scanning electron microscopy (scale 10 microns) and Malvern particle size analysis. According to the figure, the BH-HPC prepared in Example 1 forms uniform spherical nanoparticles in water with a particle size of 129.4 nm, a PD I of 0.273, and a potential of -37 mv.
[0123] Figure 2d-2f The comparative analysis data of BH-HPC and BH, HPC and BH:HPC = 1:1 physical mixture are shown. Figure 2d The results of differential scanning calorimetry (DSC) analysis suggest that there is interaction between BH and HPC, such as the formation of hydrogen bonds, indicating the formation of a complex. Figure 2e Fourier transform infrared FTIR analysis results indicate that no new chemical bonds are formed between BH and HPC. Figure 2f The XRD results indicated that the berberine hydrochloride crystal form changed and existed in the complex in an amorphous form. The above results showed that the berberine hydrochloride phospholipid complex (BH-HPC) was prepared and had good drug release ability.
[0124] Example 2-1 Preparation method of berberine hydrochloride-loaded phospholipid complex microspheres
[0125] Step 201: Electrospraying liquid: Prepare AG solutions of certain concentrations, 0.5%, 1%, and 1.5% (w / w), respectively, in a beaker, stir and dissolve, and electrospraying can be performed when there is no obvious precipitation.
[0126] Step 202: Receiving solution: weigh 4.0 g CaCl 2 Add 100 mL of CaCl prepared in pure water 2 Solution (w / w, 4%) was placed in a 250 mL culture dish for later use.
[0127] Step 203: suspending different proportions of berberine hydrochloride phospholipid complex (BH-HPC) in a sodium alginate solution to prepare drug-loaded microspheres (AG-MPs@BH-HPC).
[0128] A small amount of AG-MPs@BH-HPC was taken and dropped onto a glass slide. The morphology and size were observed under a microscope and photographed. The average particle size of the microspheres (100) in the photographs was measured using ImageJ as the particle size of each group, and the morphology of the microspheres was recorded. Figure 3aAs shown in the figure, the morphology of microspheres prepared with different AG solution concentrations (w / w%) (0.5% on the left, 1% in the middle, 1.5% on the right, scale 200 μm). It can be seen from the figure that the microspheres in the figure, according to the morphology of the microspheres in the figure, the microspheres in 0.5% (left figure) are small and uneven in size. The reason is that the sodium alginate solution is too low, and the calcium ions and sodium alginate cannot be completely cross-linked; the microspheres in 1.5% (right figure) are uneven in size and the microspheres are elliptical; the result of the sodium alginate solution concentration investigation is to select 1% sodium alginate solution. Too high alginate concentration will cause the microspheres to be elliptical, and too low alginate concentration will not form microspheres of uniform size.
[0129] Example 2-2
[0130] The above optimal process is adopted: select 1% sodium alginate solution, CaCl 2 Solution (w / w, 4%,), preparation of drug-loaded microspheres (AG-MPs@BH-HPC), investigation of single factor preparation process of calcium alginate gel microspheres
[0131] A 5 mL syringe was loaded with a sodium alginate (AG) solution suspended with BH-HPC. A stainless steel flat-blade needle was used instead of a conventional sharp needle. The flat-blade needle helps to form a more stable droplet jet, which is beneficial for the production of uniform microspheres (MPs). Setting up the receiving device: A 2 cm magnetic rod was added to the culture dish of the receiving liquid and stirring was turned on to ensure uniform distribution of microspheres in the receiving liquid and prevent particle aggregation. A metal ring was set up between the syringe pump and the receiver, which may be used to further stabilize the electric field or guide the electrospray process. The distance from the needle to the metal ring was 2 cm, the distance from the needle to the surface of the receiving liquid was 9 cm, and the distance from the needle to the bottom of the beaker was 13 cm. These distance parameters are crucial to controlling the formation and flight trajectory of droplets during electrospraying, and directly affect the size and morphology of the final product.
[0132] like Figure 3b As shown in the figure, the morphology of microspheres prepared by different needle diameters (18G on the left, 28G on the right, scale 200μm). It can be seen from the figure that according to the morphology of the microspheres in the figure, the microspheres in 18G (left picture) and 28G (right picture) are not uniform in size, and the microspheres are broken or unformed due to the small diameter of the 28G needle (right picture); the 26G (middle picture) flat-head needle can obtain microspheres with uniform shape and particle size below 200um; therefore, we choose a needle with a diameter of 26G to prepare microspheres.
[0133] The size and morphology of MPs can be controlled by adjusting the voltage and the diameter of the nozzle. The cross-linking of the microspheres needs to exceed 2 hours to complete the cross-linking inside and outside and enhance the structure. The microspheres are rinsed with ultrapure water to remove calcium chloride, and then dried and stored. The main electrostatic spray parameters that affect the morphology of microspheres include the concentration of the electrospray liquid, voltage, nozzle size, and electrospray liquid AG injection speed.
[0134] like Figure 3c As shown in the figure, the morphology of microspheres prepared at different propulsion speeds (upper left 0.25mL / min, upper right 0.5mL / min, lower left 1.0mL / min, lower right 2.0mL / min, scale 200μm). It can be seen from the upper left figure of 3c that when the propulsion speed is 0.25mL / min, the microspheres are small and uneven; when the propulsion speed is 2.0mL / min (lower right figure), the size of the microspheres is too large, and the shapes and sizes are different; compared with the 1.0mL / min (lower left figure) solution of 0.5mL / min (upper right figure), the microspheres obtained at a propulsion speed of 0.5mL / min have appropriate particle size and uniform size, so we use a propulsion speed of 0.5mL / min to prepare microspheres.
[0135] like Figure 3d As shown, the morphology of microspheres prepared at different voltages (left 10×10 3 V, middle 15×10 3 V, right 20×10 3 V, scale 200 μm) As can be seen from the figure, the voltage 10×10 3 V, the microspheres are not uniform in size; voltage 20×10 3 V, the size of the microspheres increased significantly and broke; the voltage was set to 15×10 3 V, at this time, more uniform microspheres with more suitable sizes can be prepared.
[0136] Example 3: Effect of dosage of berberine hydrochloride phospholipid complex (BH-HPC) on microspheres
[0137] In order to investigate the effect of different BH-HPC dosage on the drug loading and encapsulation efficiency of microspheres, a solution with a sodium alginate mass fraction of 1.0% was prepared, and the mass ratio of sodium alginate to BH-HPC was changed to 1:0.5, 1:1, 1:1.5, 1:2 and other four groups of solutions for investigation. The voltage was 15×10 3 V, with a pushing speed of 0.5 mL / min, the BH-HPC loaded microspheres were prepared and the microspheres were observed under a microscope.
[0138] The results are as follows Figure 4 As shown in Figure 4, after adding BH-HPC, the particle size of the microspheres did not change significantly. As shown in Figure 4 (A, B), with the increase in the proportion of phospholipid complexes, the color of the microspheres gradually deepened, which may be due to the inclusion of phospholipid complexes. Figure 4 (C, D) indicates that as the proportion of BH-HPC continues to increase, broken microspheres begin to appear, which may be because the encapsulation capacity has reached its upper limit.
[0139] Example 4: Effect of different dosages on drug loading capacity of microspheres
[0140] The AG-MPs@BH-HPC with different dosages prepared in Example 3 were dried and ground into powders. 20 mg of the powders were weighed and 50 mL of phosphate buffer with a pH of 7.4 was added and dissolved by ultrasonic vibration. The obtained sample solutions were filtered through a 0.45 μm microporous membrane, and the drug loading and encapsulation efficiency were measured by high performance liquid chromatography.
[0141] The results of drug loading and encapsulation efficiency are shown in Table 1. As the ratio of phospholipid complexes increases, the drug loading of the microspheres increases accordingly. When AG:BH-HPC is 1:1, the rate of increase is the largest, and the final drug loading reaches 13.82±0.24%. However, the encapsulation capacity of sodium alginate is limited. As the ratio of AG:BH-HPC continues to increase, the encapsulation efficiency of sodium alginate begins to decrease, and the maximum is 85.45±0.22% at 1:0.5, and 84.12% at 1:1. Although the encapsulation efficiency has decreased, the drug loading has increased significantly. If the ratio continues to increase, the encapsulation efficiency begins to decrease, and the increase in drug loading is not significant. Therefore, AG:BH-HPC (w / w) of 1:1 is selected as the best prescription.
[0142] Table 1 Drug loading and encapsulation efficiency of microspheres with different dosages (mean ± SD, n = 3)
[0143] AG:BH-HSP(w / w) Drug loading (%) Encapsulation rate (%) 1:0.5 7.23±0.17 85.45±0.22 1:1 13.82±0.24 84.12±0.31 1:1.5 15.97±0.12 79.6±0.26 1:2 16.32±0.14 73.2±0.35
[0144] Example 5
[0145] Preparation of the inner layer of microspheres with Bletilla striata polysaccharide adhesive layer coating
[0146] Bletilla striata polysaccharides (BSP) coating solution preparation
[0147] Step 501: Preparation of 4%, 8%, and 10% Bletilla striata polysaccharide solutions by mass fraction: weigh 4.0373 g, 8.0214 g, and 10.1062 g of Bletilla striata polysaccharide, add 100 mL of pure water respectively, dissolve in a water bath at 50° C., and set aside.
[0148] Step 502: Preparation of 1% chitosan solution by mass: 1.2321 g of chitosan solution was precisely dissolved in 100 mL of 1% acetic acid aqueous solution by volume and set aside.
[0149] Step 503: Preparation of chitosan labeled with 1% damine b by mass: 1.1211 g of chitosan was precisely dissolved in 100 mL of 1% acetic acid aqueous solution by volume and set aside.
[0150] Step 504: Bletilla striata polysaccharide layer coating method
[0151] The dried sodium alginate drug-loaded microspheres (AG-MPs@BH-HPC) have good water absorption properties, which are used to absorb BSP solution. Chitosan, as a cationic material, can play a connecting role between sodium alginate and Bletilla striata polysaccharide through electrostatic action, thereby increasing the absorption of Bletilla striata polysaccharide solution by the microspheres. According to the preparation method of drug-loaded microspheres in Example 4, 10 mL of SA solution is used each time to prepare AG-MPs@BH-HPC with a mass ratio of BH-HPC to AG of 1:1, and after washing with pure water, it is placed in 100 mL of chitosan solution (w / w 1%), stirred at 100 r / min for 10 min, and sent to a 45°C vacuum drying oven for drying and standby use to obtain chitosan-treated microspheres (CS-MPs@BH-HPC). Weigh 1 g of dry microspheres treated with chitosan solution, soak them in 100 mL of 4%, 8%, and 10% Bletilla striata polysaccharide solutions, respectively, stir at 100 r / min for 10 min, and dry the microspheres in a vacuum drying oven at 45°C to obtain Bletilla striata polysaccharide-coated microspheres (BSP-MPs@BH-HPC).
[0152] Adhesive microsphere formulation screening
[0153] Shear rate dependent viscosity refers to the property that the viscosity of a fluid changes with the shear rate. Weigh appropriate amounts of dried 4%, 8%, and 10% BSP-MPs@BH-HPC and CS-MPs@BH-HPC, add a small amount of aqueous solution, allow the microspheres to absorb and swell, and then use a rheometer to measure the shear rate dependent viscosity.
[0154] The results are as follows Figure 5a As shown in the figure, all samples have non-Newtonian shear thinning behavior. The shear rate-dependent viscosity of BSP-MPs@BH-HPC at different concentrations exceeds that of CS-MPs@BH-HPC. Among them, the shear rate-dependent viscosity of 8% BSP-MPs@BH-HPC suspension is the highest, exceeding that of 10% BSP-MPs@BH-HPC. This may be because the 10% mass fraction of BSP solution exceeds the maximum absorption capacity of the microspheres, or the excessively high concentration of BSP solution hinders the diffusion of BSP into the microspheres, thereby reducing the coating of the BSP layer. In this experiment, 8% mass fraction of BSP is preferred as the coating solution prescription.
[0155] Verification of pH-dependent adhesion of microspheres
[0156] A small amount of pH 6.8 and pH 7.4 phosphate buffer were added to the 8% coated BSP-MPs@BH-HPC to simulate the normal colon environment and the pH environment of colitis, and then a shear rate-dependent viscosity test was performed using a rheometer.
[0157] The results are as follows Figure 5b As shown in the figure, the shear rate-dependent viscosity of BSP-MPs@BH-HPC at pH 6.8 is greater than that at pH 7.4, which proves that BSP-MPs@BH-HPC can have better adhesion performance under the acidic conditions of colon inflammation.
[0158] Example 6 Preparation of microsphere outer layer - colon-targeted Eudragit S100 (ES) coating
[0159] Step 601: The pH sensitive outer coating solution is prepared as follows:
[0160] Adding polymer Eudragit S100 into ethanol and stirring thoroughly to obtain a mixed solution A;
[0161] Add plasticizer triethyl citrate and anti-sticking agent talcum powder to the other half of ethanol, and mix thoroughly to mix liquid B;
[0162] Adding the mixed solution B to the mixed solution A and mixing them to obtain a preparation solution for a pH-sensitive outer coating;
[0163] The weight ratio of each component is polymer Eudragit S100: triethyl citrate: talcum powder: 95% ethanol = 6.25: 0.62: 3.13: 80.
[0164] Step 602: Place 40 g of the BSP-MPs@BH-HPC prepared in Example 5 in a coating barrel, preheat it for 5 minutes, adjust the frequency of the induced draft fan to 35 Hz and the frequency of the blower to 20 Hz, so that the BSP-MPs@BH-HPC is in a suspended state, the coating temperature is 40°C, the peristaltic flow rate of the coating liquid is 3 rpm / min, and the speed of the coating barrel is 100 rpm / min. When the weight gain of BSP-MPs@BH-HPC with ES reaches 10%, 13%, and 15%, take it out and sieve it, and the colon-localized adhesion microspheres (ES-BSP-MPs@BH-HPC) for treating ulcerative colitis are obtained.
[0165] In vitro release conditions of pH sensitive outer coating pellets
[0166] According to General Rule 0931 of Part IV of the 2020 edition of the Pharmacopoeia of the People's Republic of China, the in vitro release experiment was carried out by the slurry method, and the experimental conditions were a speed of 100r / min and a temperature of 37±0.5℃. In the experiment, ES-BSP MPs@BH-HPC was placed in 900mL of pH1.2 hydrochloric acid buffer, pH6.8 phosphate buffer, and pH7.4 phosphate buffer to simulate the release environment of the drug in different parts of the digestive tract. During the experiment, 4mL samples were taken out for analysis at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 12 hours, and fresh release medium of the same temperature and volume was immediately added to keep the volume of the system constant. The in vitro release performance of ES-BSP-MPs@BH-HPC can be evaluated by measuring the cumulative release amount of berberine hydrochloride at each time point and calculating its cumulative release degree using the standard curve.
[0167] The results are as follows Figure 6 As shown in the figure, when Eudragit S100 was used as the coating material for the microspheres and the coating weight gain was 6% and 8%, a higher cumulative release of berberine hydrochloride was observed in simulated artificial gastric fluid for 2 hours and simulated artificial small intestinal fluid for 3 hours. This indicates that under these conditions, a continuous and complete ES coating film may not have been fully formed. With the increase of coating weight gain, the drug release rate of ES-BSP-MPs@BH-HPC microspheres gradually decreased. When the coating weight gain reached 10%, the cumulative release of berberine hydrochloride under pH 1.2 and pH 6.8 conditions dropped to less than 10%. ES-BSP-MPs@BH-HPC began to release in large quantities after 5 hours, which was consistent with the colon-targeted release behavior. When the coating weight gain continued to increase, no significant improvement in the targeting ability of the microspheres was observed, so it was determined that the coating weight gain of 10% was the best choice.
[0168] Example 7
[0169] Study on colon-localized adhesion of microspheres in the gastrointestinal tract of mice.
[0170] Preparation of fluorescent markers:
[0171] The specific preparation method of BH-HPC@FITC is as follows: In the preparation of BH-HPC, 10 mg of fluorescein isothiocyanate (FITC) was added to every 100 mg of BBR, and attention was paid to light-proof operation during preparation and use. BH-HPC@FITC was used instead of BH-HPC to prepare ES-BSP-MPs@BH-HPC-FITC, ES-MPs@BH-HPC-FITC and BSP-MPs@BH-HPC-FITC using electrostatic spray technology.
[0172] Animals and their groups:
[0173] 45 male Balb / c mice (SPF grade) were used, with a body weight of 25 to 35 g. The mice were fasted for 24 h before the experiment and divided into the following three groups (15 mice / group): ES-BSP-MPs@BH-HPC-FITC, ES-MPs@BH-HPC-FITC and BSP-MPs@BH-HPC-FITC;
[0174] Small Animal Imaging Operation and Acquisition Process
[0175] After oral administration (the dosage was calculated based on the BH dose of 50 mg / kg), the mice were killed at specific time points - 4 hours, 8 hours, 12 hours and 24 hours, and their gastrointestinal tissues were collected and removed in a dark environment, and then spread on a black panel for observation. The distribution of fluorescent signals of the isolated mouse GIT was observed using the IVIS spectral imaging system, which can reveal the precise location and distribution of ES-BSP-MPs@BH-HPC-FITC in the mouse gastrointestinal tract. In order to capture the FITC signal, the imaging parameters were set as follows: excitation wavelength 490nm, emission wavelength 525nm, exposure time 60 seconds, field of view 200mm, aperture set to f / 2.5, and images were recorded.
[0176] like Figure 7 As shown in the figure, from top to bottom, they are the stomach, small intestine (continuous curved part), cecum (bulging part), and colon below the cecum). In the first 4 to 8 hours, the FITC-loaded BSP-MPs@BH-HPC-FITC showed fluorescence signals in the stomach and small intestine, and only weak signals were left in the colon segment. After 12 hours, the fluorescence signal almost disappeared, and FITC was released and absorbed in the stomach and small intestine, indicating that the uncoated microspheres had no colon targeting. In contrast, the fluorescence appearance time of ES-MPs@BH-HPC-FITC and ES-BSP-MPs@BH-HPC-FIT was relatively close, with strong fluorescence signals appearing in the colon at 8 hours, and there were still certain fluorescence signals in the colon segment at 12 hours, indicating that the coated microspheres achieved drug colon delivery. In addition, the fluorescence reaction of ES-BSP-MPs@BH-HPC-FIT was still observed in the colon after 24 hours, while the other groups did not. This phenomenon may be due to the good adhesion of BSP itself, which leads to a longer retention of the drug in the colon. This finding revealed that ES-BSP-MPs@BH-HPC-FIT could be effectively delivered to the colon and achieve slow and sustained release of drugs in the cecum and colon, reflecting the potential of this preparation in colon-targeted drug delivery.
[0177] Table 2 Grouping of model mice
[0178]
[0179]
[0180] Establishment of DSS-induced colitis model in mice
[0181] Before the mice were modeled for ulcerative colitis, all mice were fasted for one day but not water. Then, except for the control group, the other seven groups of mice were allowed to drink freely a solution containing 3% (w / v) DSS to build the model. This process lasted for 7 days. During this period, the activity status, weight changes, fecal characteristics and occult blood test results of the mice were observed and recorded at a fixed time every day to evaluate whether the disease model was successfully established.
[0182] Observation data showed that on the third day of modeling, some mice began to show symptoms of diarrhea, and then the feces became thinner; on the fourth day, some mice were observed to have bloody stools, their activities became slow, they lost weight, their mental state was obviously poor, and their hair lost its luster, showing a significant deterioration in health compared with the control group.
[0183] Dosage and dosing regimen of treatment groups
[0184] There were 7 groups in total, including free BH group, mesalamine control group (100 mg / kg), Xianglian Pills control group (60 mg / kg), Mesalamine and Xianglian Pills group, ES-BSP-MPs@BH-HPC group, and ES-MPs@BH-HPC group. The BH dose of the drug-treated group was 50 mg / kg / d. The drug was mixed with warm water and gavage was performed using a No. 12 gavage needle, and the mice were weighed daily.
[0185] Disease Activity Index (DAI) Assessment
[0186] Referring to the DAI scoring method described in Table 3, the scores of weight loss, stool consistency and occult blood test were combined and averaged to calculate the overall score of each mouse, thereby judging the activity of the disease and whether the treatment group drugs can effectively improve the weight loss and disease state of the mice.
[0187] Table 3 Mouse DAI score table
[0188] Weight loss Stool characteristics Blood in stool and occult blood Score <1% normal Negative 0 1-5% Occult blood weak positive 1 5-10% Loose Occult blood positive 2 10-15% Strong positive occult blood 3 >15% diarrhea Visible blood in the stool or heavy bleeding 4
[0189] Note: Normal stool: granular, formed stool; Loose stool: Pasty, semi-formed stool that does not adhere to the anus; Diarrhea: watery stool that adheres around the anus.
[0190] The evaluation method and index of fecal occult blood are as follows: add 2-3 drops of o-tolidine solution on a white porcelain plate, then add 1-2 drops of hydrogen peroxide solution. If there is no color change, immediately pick a small amount of feces and mix it with the above reagents, observe the color change, and refer to Table 1-2 to evaluate the fecal occult blood situation;
[0191] Table 4 Evaluation table of blood in stool
[0192] Negative No blue-green color after 3 minutes Weak positive Turns blue within 30-60s Positive Immediately turns blue-green Strong positive Immediately turns dark blue
[0193] like Figure 8a-8b As shown, the weight of mice in the control group showed a stable growth trend. The increase in DAI score reflects the increased severity of colitis. During the entire study, the DAI value of the healthy mouse group remained unchanged, and its weight also showed a continuous increase trend. Compared with the control group, the weight of mice in the DSS group decreased significantly, and the DAI score increased. After seven days of free BH treatment, the symptoms of mice in the BH group did not improve significantly. The DAI of mesalazine decreased from 3.2 to 1.3, the DAI of ES-BSP-MPs@BH-HPC decreased from 3.38 to 0.75, and the DAI of ES-MPs@BH-HPC decreased from 3.375 to 1.816 (see Figure 8c ), indicating that the symptoms were relieved. In addition, ES-BSP-MPs@BH-HPC showed advantages in optimizing the therapeutic effect compared with the positive control drug Mesalazine and the mixed control group of traditional Chinese medicine formula, especially when used in combination with Mesalazine, it can effectively improve the therapeutic effect (see Figure 8c , 8d In addition, although the therapeutic effect of ES-MPs@BH-HPC was not as good as that of Mesalazine, the ES-BSP-MPs@BH-HPC with the addition of BSP had the best therapeutic effect among all groups. This may be because Bletilla striata polysaccharide increased the colon adhesion of microspheres, or it may be attributed to the similar principle as the mixed treatment group, achieving a synergistic effect and more effectively alleviating the UC symptoms caused by DSS.
[0194] Changes in colon length and spleen weight in mice
[0195] In the final stage of the experiment, in order to evaluate the effects of each treatment group on the UC mouse model, the mice were fasted for 24 hours after administration on the seventh day. After being killed, the colon and spleen were removed and the length and weight were measured. The colon length can be used to evaluate the severity of UC and the effect of treatment, and the increase in spleen weight can be used as another indicator to evaluate the degree of inflammation and the effect of treatment.
[0196] As Fig. 9(A, B) show that the colon length of the control group was about 10 cm. The colon length of the model group treated with DSS was significantly shortened to about 5 cm (p<0.001), and the BH group failed to significantly improve the shortening of the colon. The mice treated with ES-BSP-MPs@BH-HPC had the longest colon length, close to the length of the normal control group. Secondly, the effect of the mixed control group was better than that of the group using Mesalazine and Xianliian pills alone, indicating that the combined treatment has a better therapeutic effect. As an important part of the internal immune system, the increase in the weight of the spleen is a sign of inflammatory state. Fig. 9 C and Fig. 9 As shown in D, the spleen weight of the healthy control group was about 0.10 g, while the spleen weight of the DSS-treated model group increased significantly to 0.18 g (p<0.001), indicating severe systemic inflammation. The severity of colitis in the treated groups of mice was reduced, especially in the mice treated with ES-BSP-MPs@BH-HPC, whose spleen weight was most significantly reduced (p<0.001), close to the level of the healthy control group, indicating that the treatment regimen has a significant effect on alleviating DSS-induced colitis.
[0197] HE staining and histopathological observation and scoring of colitis
[0198] The experimental mice were sacrificed after a 7-day treatment period, and the colon tissue segments were immediately removed from them and immersed in 4% paraformaldehyde fixative to fix the tissue samples. Next, the samples were dehydrated with analytical grade ethanol and xylene and finally embedded in paraffin. A freezing knife was used to cut along the longitudinal direction of the slices to produce 4-micron thick tissue sections. These sections were then stained with hematoxylin-eosin (H&E) and observed in detail under an optical microscope. By taking photos and comparing them with the existing scoring criteria (Table 5), a blind method was used to score according to the epithelial cell morphology, inflammatory cell infiltration, etc. in the slices to quantify the degree of inflammation in the mouse colon.
[0199] Table 5 Colon histopathology scoring criteria
[0200]
[0201] Hematoxylin-eosin (H&E) staining was used to evaluate the morphology of colon tissues in different experimental groups. Fig.10As shown in the figure, the colon tissue of the normal control group mice maintained typical structural characteristics, with intact colon epithelium, clear crypt and goblet cell structures, and no obvious signs of inflammation. The colon tissue of the DSS-treated group showed significant pathological changes, including loss of colon epithelial cells, distorted crypt structure, discontinuous mucosa and irregular morphology, accompanied by a large number of neutrophil infiltration, which are typical signs of colon inflammation, thus confirming the successful construction of the ulcerative colitis model. The colon treatment effect of the BH and ES-MPs@BH-HPC treatment groups was limited. In contrast, the colon damage of mice in the positive control drug Mesalazine treatment group was improved, but inflammatory cell infiltration and slight crypt distortion were still observed compared with the DSS model group. The colon structure of the mixed control group was relatively complete, with an increase in the number of crypts and goblet cells. Although there was still some epithelial cell necrosis and inflammatory cell infiltration, the inflammatory symptoms were alleviated. In particular, the colon tissue of mice treated with ES-BSP-MPs@BH-HPC recovered to a similar degree as that of healthy mice, and the inflammatory response was significantly reduced, as shown by epithelial regeneration and reduced inflammatory cell infiltration. Quantitative analysis further confirmed this observation, showing that the ES-BSP-MPs@BH-HPC group had significantly lower degree of colon tissue damage than the DSS-treated group (p<0.001). Fig.11 ), the DSS group had the highest score, reflecting the most severe tissue damage, while the ES-BSP-MPs@BH-HPC group had the lowest score, showing the effectiveness of this treatment strategy in protecting colon tissue. In conclusion, ES-BSP-MPs@BH-HPC treatment significantly protected colon tissue, alleviated DSS-induced structural damage, and promoted epithelial repair and inflammation relief, indicating that its combined treatment is more effective than single treatment, which may be attributed to the strategy's ability to ensure adequate concentration and prolonged residence time of the drug in the inflamed colon site, thereby effectively alleviating the inflammatory response.
[0202] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A colon-localized adhesion microsphere for treating ulcerative colitis, characterized in that: The colon-localized adhesive microspheres for treating ulcerative colitis include calcium alginate microspheres containing berberine hydrochloride phospholipid complexes, an adhesive inner coating and a pH-sensitive outer coating, wherein the calcium alginate microspheres containing berberine hydrochloride phospholipid complexes are coated with a Bletilla striata polysaccharide coating with adhesive ability and a pH-sensitive outer coating in sequence.
2. The colon-localized adhesion microspheres for treating ulcerative colitis according to claim 1, characterized in that: The raw materials of the calcium alginate microspheres containing berberine hydrochloride phospholipid complex include sodium alginate solution, berberine hydrochloride phospholipid complex, and calcium chloride solution, wherein: The mass fraction of the sodium alginate solution includes 0.5 to 2%; the mass fraction of the calcium chloride solution includes 2 to 6%; The mass ratio of sodium alginate to berberine hydrochloride phospholipid complex is 0.5:1-2:
1.
3. The colon-localized adhesion microspheres for treating ulcerative colitis according to claim 2, characterized in that: The raw materials of the berberine hydrochloride phospholipid complex include berberine hydrochloride and hydrogenated lecithin; wherein the mass ratio of berberine hydrochloride to hydrogenated lecithin is 0.5:1 to 1:
4.
4. The colon-localized adhesion microspheres for treating ulcerative colitis according to claim 2, characterized in that: The raw materials of the adhesive inner layer coating include 6% to 10% by mass of a Bletilla striata polysaccharide solution, and the remainder is pure water.
5. The colon-localized adhesion microspheres for treating ulcerative colitis according to claim 1, characterized in that: The coating weight gain of the pH sensitive outer coating is 10%-15% of the weight of the colon-localized adhesive microspheres for treating ulcerative colitis; The preparation liquid of the pH sensitive outer layer coating comprises the following raw materials: acrylic resin, plasticizer, anti-sticking agent and organic solvent; The weight ratio of each component includes acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
6. The colon-localized adhesion microspheres for treating ulcerative colitis according to claim 5, characterized in that: The acrylic resin includes Eudragit enteric series products; The plasticizer includes triethyl citrate, sorbitol or polyethylene glycol; The anti-adhesive agent includes talc or dextrin; The organic solvent includes ethanol at a volume concentration of 70-95%.
7. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to any one of claims 1 to 6, characterized in that: The following steps are involved: Based on berberine hydrochloride and hydrogenated lecithin, berberine hydrochloride phospholipid complex is prepared; Based on sodium alginate solution, calcium chloride solution and berberine hydrochloride phospholipid complex, calcium alginate microspheres containing berberine hydrochloride phospholipid complex are prepared; The calcium alginate microspheres containing the berberine hydrochloride phospholipid complex are coated with an adhesive inner layer to obtain a coating of Bletilla striata polysaccharide having an adhesive ability; The Bletilla striata polysaccharide coating with adhesion ability is coated with a pH-sensitive outer layer to form colon-localized adhesion microspheres for treating ulcerative colitis.
8. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 7, characterized in that: The calcium alginate microspheres containing the berberine hydrochloride phospholipid complex are coated with an adhesive inner layer to obtain a Bletilla striata polysaccharide coating having an adhesive ability, comprising: Pre-coating the calcium alginate microspheres containing berberine hydrochloride phospholipid complex with chitosan; The pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex are immersed in a Bletilla striata polysaccharide solution to obtain a Bletilla striata polysaccharide coating having adhesion ability.
9. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 8, characterized in that: The calcium alginate microspheres containing berberine hydrochloride phospholipid complex are pre-coated with chitosan, comprising: Prepare a chitosan aqueous solution; wherein the mass fraction of the chitosan solution is 0.5-1.5%; The calcium alginate microspheres containing berberine hydrochloride phospholipid complex are placed in a chitosan solution and stirred for a first predetermined time, filtered, and dried to obtain pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex.
10. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 8 or 9, characterized in that: The pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex are immersed in a Bletilla striata polysaccharide solution to obtain a Bletilla striata polysaccharide coating having adhesion ability, comprising: preparing a Bletilla striata polysaccharide solution, wherein the mass fraction of the Bletilla striata polysaccharide solution is 8%; A predetermined mass of pre-coated calcium alginate microspheres containing berberine hydrochloride phospholipid complex is taken and immersed in a Bletilla striata polysaccharide solution. After stirring for a second predetermined time, the solution is filtered and dried to obtain a Bletilla striata polysaccharide coating having adhesion ability.
11. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 8, characterized in that: The Bletilla striata polysaccharide coating with adhesion ability is coated with a pH-sensitive outer layer to form colon-localized adhesion microspheres for treating ulcerative colitis, comprising: The polysaccharide coating of Bletilla striata with adhesion ability is placed in a preparation solution containing a pH-sensitive outer coating and preheated to make the microspheres in a suspended state; The microspheres are coated under preset coating conditions until the pH-sensitive layer coating covering the Bletilla striata polysaccharide coating with adhesion ability reaches a preset coating weight gain, thereby obtaining colon-localized adhesion microspheres for the treatment of ulcerative colitis.
12. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 8, characterized in that: The formulation containing the pH sensitive outer coating is prepared as follows: Adding acrylic resin into an organic solvent and stirring thoroughly to obtain a mixed solution A; Add plasticizer and anti-adhesive agent to the other half of the organic solvent and mix well to form a mixed solution B; Adding the mixed solution B to the mixed solution A and mixing them to obtain a preparation solution for a pH-sensitive outer coating; The weight ratio of each component includes: acrylic resin: plasticizer: anti-adhesive agent: organic solvent = 6.25-12.50: 0.62-1.24: 3.13-6.26: 80-160.
13. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 8, characterized in that: The preset coating conditions are: temperature of 40-55°C, peristaltic flow rate of coating liquid of 3-8rpm / min, and rotation speed of coating barrel of 50-150rpm / min.
14. The method for preparing colon-localized adhesion microspheres for treating ulcerative colitis according to claim 13, characterized in that: The preset coating weight gain is 8-12% of the coating weight gain of the pH-sensitive layer coating that wraps the Bletilla striata polysaccharide coating with adhesion ability.
15. Use of the colon-localized adhesive microspheres for treating ulcerative colitis as claimed in any one of claims 1 to 6 in the preparation of a drug for treating ulcerative colitis.
Citation Information
Patent Citations
Berberine liposome and preparation method thereof
CN102475682A
Colon-targeted oral probiotic microcapsule and preparation method and application thereof
CN113274369A
Oral colon-specific preparation for preventing and treating ulcerative colitis
CN113616619A
Novel pH / enzyme dual-sensitive colon-targeted pellet and preparation method thereof
CN116617186A
Drug carrier for treating of gastrointestinal ulcer
US20120009264A1
